With this issue of Phlebology, the journal has a new publisher and also a new Editor. The scope of the journal will be similar to that published under the previous editorship of Philip Coleridge Smith -to whom we, as both contributors and readers, are indebted for all his hard work over many years; a big thank you. The journal aims to appeal to a wide range of health care professionals and research scientists involved in all the various aspects of venous and lymphatic disease. Phlebology continues to be the official journal of the Venous Forum at the Royal Society of Medicine, and it is hoped that in the future other societies may wish to become affiliated more directly with the journal.
We are seeing an increasing number of patients presenting with venous and lymphatic problems. Patients have greater expectations of treatment modalities, and there is increased awareness of the need for a multidisciplinary team approach to their management. It is essential that we increase our understanding of the basic science of the underlying disease processes, since this will not only improve clinical knowledge but also bring about changes in treatments.
So in the new era of this journal, in what areas of our specialty may we hope to see some significant improvement in outcomes for patients?
With respect to venous thrombosis, the debate on the risk of deep vein thrombosis related to air travel may fully unfold, as may the optimal treatment for Paget-Schroetter syndrome. Further research is needed into the importance of patient factors and the basic science underlying the balance between thrombolysis and thrombosis.
The Holy Grail of the successful management of leg ulcers has for many years evaded those who care for such patients. In the near future the potential benefits of surgery may be confirmed. The role of various pharmacological agents in enhancing the healing process may be helpful, as well as different techniques of skin coverage.
We have seen the development of many potential new techniques on how to obliterate the long saphenous vein, the long-term results of which will establish them either as mainstays of treatment or a passing fad suitable for treating only a minority of patients. Further, we may discover the answer to which symptoms are truly attributable to venous incompetence in the lower limbs. The method of assessing outcomes and health care costs/benefits will need further evaluation. 
Change of publisher and Editor -a new era
Laser therapy in the treatment of venous abnormalities has seen many highs and lows. Its main role is now reserved for fine vein telangiectasia not suitable for sclerotherapy, but improving technology may see an end to this more conservative trend.
The role of vascular biology in terms of a better understanding of the disease processes involved, ranging from thrombosis to healing of ulcers, may well be the key to prevention and treatment of these conditions in the future.
Diagnostic imaging of veins and the quantitative assessment of the extent of the underlying venous disease are also likely to feature as important issues in the future. The aim is to find a method of noninvasive assessment that provides not only good anatomical knowledge but also information on physiological function.
These are some of the important issues I believe are confronting the health care professionals and scientists involved in addressing the problems of venous disease. They do not represent an exhaustive list but they do reflect a potential vision for the future.
I hope you will find the new format and design of the journal to your liking. The Editorial Board, publishers and I would be grateful if you would contact me via the editorial office if you have any comments or suggestions. I regard the editorship of Phlebology as an exciting opportunity, and look forward to the support of both contributors and readers in developing the journal and increasing understanding of all aspects of venous disease to the benefit of patients.
I trust you will read with interest and enjoy.
Alun H Davies Editor, Phlebology
Editor's profile Alun Davies MA DM FRCS, the new editor of Phlebology, is a Reader and Honorary Consultant in Surgery based at Charing Cross Hospital in the Faculty of Medicine, Imperial College, London. He has been the author of many papers and edited numerous books on vascular disease. He is a member of the Councils of both the Venous Forum of the Royal Society of Medicine and the Vascular Surgical Society of Great Britain and Ireland. He is also a member of many other societies, including the American Venous Forum and the European Venous Forum.
